VentriPoint Diagnostics Ltd. (CVE:VPT – Get Free Report) hit a new 52-week low on Friday. The company traded as low as C$0.07 and last traded at C$0.08, with a volume of 259,484 shares changing hands. The stock had previously closed at C$0.08.
VentriPoint Diagnostics Stock Performance
The company has a current ratio of 0.12, a quick ratio of 6.67 and a debt-to-equity ratio of -68.25. The firm has a market capitalization of C$15.43 million, a price-to-earnings ratio of -4.00 and a beta of -1.07. The company has a 50-day moving average of C$0.09 and a 200-day moving average of C$0.11.
About VentriPoint Diagnostics
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients.
See Also
- Five stocks we like better than VentriPoint Diagnostics
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for VentriPoint Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VentriPoint Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
